AR097029A1 - Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune - Google Patents

Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune

Info

Publication number
AR097029A1
AR097029A1 ARP140102733A ARP140102733A AR097029A1 AR 097029 A1 AR097029 A1 AR 097029A1 AR P140102733 A ARP140102733 A AR P140102733A AR P140102733 A ARP140102733 A AR P140102733A AR 097029 A1 AR097029 A1 AR 097029A1
Authority
AR
Argentina
Prior art keywords
immune response
birds
accelerating
acceleration
composition
Prior art date
Application number
ARP140102733A
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR097029A1 publication Critical patent/AR097029A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una vacuna que comprende un vector del virus herpes aviar vivo, un oligodesoxinucleótido, y un portador farmacéuticamente aceptable, donde el vector del virus herpes aviar vivo comprende una secuencia nucleotídica heteróloga que codifica un antígeno de un microorganismo que es patógeno para las aves, y donde el oligodesoxinucleótido es un agonista del receptor tipo Toll (TLR) 21 aviar. Reivindicación 12: Un agonista del TLR21 según lo descrito en cualquiera de las reivindicaciones 3 - 5, para utilizar en la aceleración de la respuesta inmune en aves, contra un antígeno expresado por un vector de virus herpes aviar vivo según lo descrito en cualquiera de las reivindicaciones 1 ó 2.
ARP140102733A 2013-07-26 2014-07-23 Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune AR097029A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13178137 2013-07-26

Publications (1)

Publication Number Publication Date
AR097029A1 true AR097029A1 (es) 2016-02-17

Family

ID=48874196

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102733A AR097029A1 (es) 2013-07-26 2014-07-23 Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune

Country Status (9)

Country Link
US (1) US9757449B2 (es)
EP (1) EP3024935B1 (es)
CN (1) CN105452468B (es)
AR (1) AR097029A1 (es)
BR (1) BR112016001686B1 (es)
ES (1) ES2745275T3 (es)
PL (1) PL3024935T3 (es)
RU (1) RU2701805C2 (es)
WO (1) WO2015011261A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
WO2018112051A1 (en) 2016-12-14 2018-06-21 Merial, Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
US11542507B2 (en) * 2017-12-15 2023-01-03 Bayer Animal Health Gmbh Immunostimulatory compositions
CN111542337A (zh) 2017-12-20 2020-08-14 英特维特国际股份有限公司 用于细胞相关联的α疱疹病毒疫苗的改良稀释剂
MX2022016337A (es) 2020-06-17 2023-04-10 Boehringer Ingelheim Vetmedica Gmbh Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogenicas, su produccion y usos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
GB8603341D0 (en) 1986-02-11 1986-03-19 Portapax Ltd Foam sheet
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
EP2759306B1 (en) * 2008-12-09 2016-04-06 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
CN107513533A (zh) * 2011-05-26 2017-12-26 英特维特国际股份有限公司 免疫刺激性寡脱氧核苷酸
WO2013057236A1 (en) 2011-10-21 2013-04-25 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CN103874508A (zh) 2011-10-21 2014-06-18 英特维特国际股份有限公司 提供多价免疫的重组非致病性mdv载体
WO2013082327A1 (en) * 2011-11-30 2013-06-06 Merial Limited Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Also Published As

Publication number Publication date
EP3024935A1 (en) 2016-06-01
WO2015011261A1 (en) 2015-01-29
EP3024935B1 (en) 2019-07-17
CN105452468A (zh) 2016-03-30
RU2701805C2 (ru) 2019-10-01
US9757449B2 (en) 2017-09-12
PL3024935T3 (pl) 2020-01-31
ES2745275T3 (es) 2020-02-28
BR112016001686A2 (pt) 2017-09-19
US20160158347A1 (en) 2016-06-09
CN105452468B (zh) 2018-08-21
BR112016001686B1 (pt) 2023-02-07
RU2016106419A (ru) 2017-08-29

Similar Documents

Publication Publication Date Title
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
AR101455A1 (es) Molécula portadora
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
DOP2016000223A (es) Plásmidos inmunoestimuladores
AR081856A1 (es) Vacuna y metodos para reducir una infeccion por campylobacter
BR112016006192A2 (pt) composição de vacina de divergente de pcv2b e métodos de uso
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
CA3010977A1 (en) Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
DOP2020000113A (es) Oligonucleótidos inmunoestimulantes
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2017009306A (es) Vacuna contra la fiebre aftosa.
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
AR109540A1 (es) Moléculas promotoras para expresar antígenos virales
AR072976A1 (es) Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
ES2673899T3 (es) Receptores de tipo toll y oligonucleótidos inmunoestimuladores
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
PE20190225A1 (es) Un metodo para reducir la contaminacion de huevo
CL2015003616A1 (es) Cepa de piscirickettsia salmonis depositada bajo el numero de registro dms 27338; vacuna que la comprende; uso para prevenir infeccion por p. salmonis; y medio de cultivo para p. salmonis.

Legal Events

Date Code Title Description
FC Refusal